SOPHiA GENETICS S.A.
NASDAQ:SOPHMedical - Healthcare Information Services
+$0.02 today
- Market cap
- $635.90M
- Beta
- 0.98
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.14
Volume 0.61M
Average 0.10M
SOPH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
SOPHiA GENETICS S.A.NASDAQ: SOPH
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$14.65M, compared with -$13.93M a year earlier. Trailing-twelve-month EBITDA was -$66.08M.
Context
- EBITDA amounted to 83.3% of revenue in FY2025, up 5.5 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$52.14M (+19.0%) for the fiscal year ending Dec 2026, a step up from the -26.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14.65M+5.3% QoQ
- Last fiscal yearDec 2025
- -$64.4M-26.9% YoY
- LTMMar 2026
- -$66.08M-31.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.2% | +28.3% | +33.5 pp |
| 1 year | -26.9% | +19.0% | +45.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (64.4M) USD
- Year-over-year change
- -26.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (64.4M) | -26.9% |
| FY2024 | 2024-12-31 | (50.76M) | +27.0% |
| FY2023 | 2023-12-31 | (69.57M) | +14.5% |
| FY2022 | 2022-12-31 | (81.38M) | -17.5% |
| FY2021 | 2021-12-31 | (69.24M) | — |
EBITDA vs competitors
How SOPH compares with its peers on the latest reported figures
- SOPH's LTM Mar 2026 EBITDA of -$66.08M is the 7th highest of the 10 companies compared; the peer median is $18.9M.
- Its year-over-year change of -31.0% is the 8th highest of 10, against a peer median of +7.2%.
- EBITDA amounts to 81.4% of revenue for SOPH, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $101.27M | +78.1% | -1.9% | 24.1% | |
| LTM Mar 2026 | $69.88M | +7.2% | +7.6% | 22.4% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $50.25M | +362.6% | — | 12.6% |
| LTM Mar 2026 | $27.87M | -32.4% | -15.0% | 20.1% | |
| LTM Mar 2026 | $18.9M | +423.3% | — | 17.6% | |
| LTM Mar 2026 | $11.6M | +101.6% | — | 4.9% | |
| LTM Mar 2026 | -$66.08M | -31.0% | — | 81.4% | |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Sep 2026 | -$108.97M | -19.4% | — | 7.2% | |
| LTM Mar 2026 | -$192.37M | -1267.9% | — | 63.6% | |
| Peer median (excluding SOPH) | $18.9M | +7.2% | -1.9% | 20.1% | |
Competitors are the stored peer set for SOPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.45M | 47.56M | 62.37M | 65.17M | 77.27M |
| Cost of Revenue | 15.23M | 16.31M | 19.46M | 21.24M | 29.46M |
| Gross Profit | 25.22M | 31.25M | 42.91M | 43.94M | 47.81M |
| Gross Margin | 62.4% | 65.7% | 68.8% | 67.4% | 61.9% |
| Research & Development | 26.58M | 35.37M | 36.97M | 34.37M | 33.57M |
| Selling, General & Admin | 70.24M | 84.08M | 81.72M | 76.32M | 85.17M |
| Operating Expenses | 96.71M | 119.08M | 117.74M | 110.51M | 118.74M |
| Depreciation & Amortization | 3.61M | 5.57M | 8.34M | 8.6M | 9.53M |
| EBITDA | (69.24M) | (81.38M) | (69.57M) | (50.76M) | (64.4M) |
| EBITDA Margin | -171.2% | -171.1% | -111.5% | -77.9% | -83.3% |
| Operating Income | (71.49M) | (87.82M) | (74.83M) | (66.57M) | (70.93M) |
| Operating Margin | -176.7% | -184.7% | -120.0% | -102.1% | -91.8% |
| Interest Income | 20K | 1.32M | 4.55M | 3.36M | 1.87M |
| Interest Expense | 658K | 639K | 588K | 1.91M | 4.55M |
| Other Income / Expenses | (2.02M) | 238K | (3.67M) | 5.3M | (7.56M) |
| Income Before Tax | (73.51M) | (87.59M) | (78.5M) | (61.27M) | (78.49M) |
| Pre-Tax Margin | -181.7% | -184.2% | -125.9% | -94.0% | -101.6% |
| Income Tax Expense | 168K | (136K) | 486K | 1.22M | 512K |
| Net Income | (73.68M) | (87.45M) | (78.98M) | (62.49M) | (79M) |
| Net Margin | -182.1% | -183.9% | -126.6% | -95.9% | -102.2% |
| EPS (Basic) | (1.33) | (1.36) | (1.22) | (0.95) | (1.17) |
| EPS (Diluted) | (1.33) | (1.36) | (1.22) | (0.95) | (1.17) |
| Weighted Avg Shares | 55.3M | 64.1M | 64.75M | 65.78M | 67.54M |
| Weighted Avg Shares (Diluted) | 55.3M | 64.1M | 64.75M | 65.78M | 67.54M |
SOPHiA GENETICS S.A.
NASDAQ:SOPH
Intrinsic Alpha fair value
Locked
Current Price
$7.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.